MCGI focuses on personalized cancer therapy. By testing the genomic profile of your individual cancer it is possible to identify the treatment most likely to work for you. The MCGI team is working with all oncology practices in Maine to ensure that people diagnosed with cancer in the state have access to genomic tumor testing, innovative clinical trials and individualized therapies.
Explore the many patient-focused resources developed by MCGI below. Each page contains resources to help patients and caregivers understand more about cancer, the cancer journey, and the help available.
Collaboration is central to MCGI, which extends cancer genomic testing, education, and drug access infrastructure across Maine and beyond.
A collection of latest news and publications focusing on Maine Cancer Genomics Initiative (MCGI).
Find local and online support groups, lodging, travel, and financial support resources.
Explore different MCGI educational resources and materials for cancer patients.
Learn moreJoin the MCGI PAC to help improve cancer patients' experiences and understanding of available resources.
Betty Walls is fighting cancer with an upbeat attitude and advanced genomic treatment.
What is hereditary cancer testing? Sometimes also referred to as genetic testing or DNA cancer testing, hereditary cancer testing can be done to detect and assess higher cancer risk for certain cancers that may have been passed down through your family.
Biomarker testing is a valuable tool that can help oncologists determine the right treatment that is personalized for your cancer.
Clinical trials are research studies that compare the standard treatment for a specific type or stage of cancer with a new approach. This can be a new drug, a combination of drugs or a different way of using established therapies. After a cancer diagnosis, it’s important to carefully consider all potential treatment options to know what’s best for you and discuss with your care team.
Maine cancer patients experienced better outcomes following genomic tumor testing to guide targeted therapy strategies; but a gap between testing and clinical delivery still exists.
View more
In a paper published in JCO Precision Oncology, the Maine Cancer Genomics Initiative (MCGI) team, led by Professor and former JAX President and CEO Ed Liu, M.D., and Chief Medical Officer Jens Rueter, M.D., presents the highly successful launch and implementation of the first phase of MCGI.
View more
JAX experts on harnessing genetics to understand personalized cancer care and regenerative medicine.
View more